Announcement of the resolution of the third session of the 10th board of directors
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2018-004
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
十届3次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2018年4月9日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2018年4月20日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决方式召开。
(四)本次董事会会议应出席的董事9人,实际出席会议的董事9人,会议有效表决票数9票。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2017年度总经理业务报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了2017年度财务决算报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本报告需提交股东大会审议
3、通过了2017年度利润分配预案
经天健会计师事务所(特殊普通合伙)审计,2017年度公司合并报表归属于母公司股东的净利润为348,494,304.06元;母公司会计报表净利润194,066,681.11元。按母公司的本期净利润194,066,681.11元为基数,提取10%法定公积金19,406,668.11 元,加年初未分配利润570,339,566.43元,减去2016年度现金分红86,020,957.00元,本年度可供分配利润为658,978,622.43元。
公司2017年度拟进行现金分配,以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8 元(含税)。
2017年度不进行公积金转增股本。
董事会说明:
(1)现金分红政策执行情况
《公司章程》规定:公司最近三年以现金方式累计分配的利润不少于最近三年实现的年均可分配利润的百分之三十。
从2011年以来,公司连续进行了现金分红,已累计实施现金分红38881.47万元,最近三年现金分红情况如下(2017年度暂按上述预案计算,单位:万元):
|
分红年度 |
现金分红数额 |
当年合并归母公司净利润 |
现金分红占当年合并归母公司净利润比例 |
|
2015年 |
6193.51 |
20089.94 |
30.83% |
|
2016年 |
8602.10 |
28522.95 |
30.16% |
|
2017年 |
3440.84 |
34849.43 |
9.87% |
|
|
最近三年以现金方式累计分配 |
最近三年实现的年均可分配利润 |
最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例 |
|
|
18236.44 |
27820.77 |
65.55% |
公司最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例为65.55%,符合公司《公司章程》规定的现金分红政策。
(2)公司的发展情况
目前,公司正处于发展的关键阶段,2018年公司将加快推进上海北卡项目,其子公司安徽新北卡化学有限公司需进行技术改造,建设“年产350吨医药中间体及900吨农药原药项目”;尖峰药业“DPT”项目进入一期临床试验,尖峰药业及其子公司浙江尔婴(原金得尔)、尖峰亦恩将进一步加大产品研发和引进力度;2018年度公司还将继续投入并完成尖峰国贸“新建仓库(电商物流园)项目”;上述业务的开展需要较大的资金支持。
(3)考虑到2018年公司在技改、新产品开发等方面的投入较大,为了保持公司的稳健经营,支持公司的长远发展,兼顾股东的短期和长期利益,董事会通过了上述2017年度利润分配预案。
(4)公司将召开2017年度业绩及现金分红说明会,就公司2017年度业绩及现金分红事项与投资者进行沟通和交流,及时答复投资者关心的问题。
(5)公司在召开股东大会审议上述2017年度利润分配预案时,将为投资者提供网络投票便利条件,同时按照参与表决的A股股东的持股比例分段披露表决结果。
独立董事意见:
(1)同意公司以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8元(含税),2017年度不进行公积金转增股本。
(2)该利润分配预案是根据公司2017年度实际经营成果及财务状况,结合公司未来业务发展的实际需要而制定。留存未分配利润主要用于满足公司公司发展的资金需求,有利于公司的持续健康发展,不存在损害股东特别是中小股东权益的情况。我们认为其符合《公司章程》对于利润分配的相关规定,符合公司的实际经营状况。
(3)公司董事会审议通过了上述利润分配预案。我们认为本次会议的召集、召开及审议表决程序符合相关法律、法规及《公司章程》的规定,合法有效;并同意将该预案提交公司2017年年度股东大会审议。
表决结果:同意9票、反对0票、弃权0票。
该预案将提交股东大会审议。
4、通过了聘请公司2018年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所(特殊普通合伙)为公司2018年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
5、通过了2017年年度报告及其摘要
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。2017年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
6、通过了关于对控股子公司提供担保的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《对控股子公司提供担保的公告》(临2018-008)。
7、关于授权董事长利用自有资金进行委托理财的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于授权董事长利用自有资金进行委托理财的公告》(临2018-007)。
8、关于子公司日常关联交易的议案
董事会审议并通过了该议案。
表决结果:同意7票、反对0票、弃权0票。关联董事蒋晓萌、杜自弘回避了该议案的表决。
详见《关于子公司日常关联交易公告》(临2018-006)。
9、通过了关于召开2017年度股东大会的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于召开2017年度股东大会的通知》(临2018-010)。
10、通过了2017年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
11、通过了关于新北卡化学技术改造项目的议案
董事会审议并通过了该议案。同意子公司安徽新北卡化学有限公司投资16274.25万元,其中:固定资产投资为13274.25万元,流动资金3000万元。建设“年产350吨医药中间体及900吨农药原药项目”。
表决结果:同意9票、反对0票、弃权0票。
12、通过了2017年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据《中长期激励管理办法》的规定,2017年度可提取中长期激励基金为13836266.94元。
表决结果:同意9票、反对0票、弃权0票。
13、通过了董事会审计委员会2017年度履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
14、通过了独立董事2017年度述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
独立董事将向股东大会报告。
15、通过了2017年度董事会工作报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的独立意见:
公司独立董事对上述4、6、7、8、12五项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、上网公告附件
公司第十届独立董事对上述相关事项的独立董事意见。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一八年四月二十四日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11